Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Literature DB >> 30633973

Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Jiayi Pan¹, Livia P Mendes², Momei Yao¹, Nina Filipczak³, Sumanta Garai⁴, Ganesh A Thakur⁴, Can Sarisozen¹, Vladimir P Torchilin⁵.

Abstract

Multidrug resistance (MDR) significantly decreases the therapeutic efficiency of anti-cancer drugs. Its reversal could serve as a potential method to restore the chemotherapeutic efficiency. Downregulation of MDR-related proteins with a small interfering RNA (siRNA) is a promising way to reverse the MDR effect. Additionally, delivery of small molecule therapeutics simultaneously with siRNA can enhance the efficiency of chemotherapy by dual action in MDR cell lines. Here, we conjugated the dendrimer, generation 4 polyamidoamine (G4 PAMAM), with a polyethylene glycol (PEG)-phospholipid copolymer. The amphiphilic conjugates obtained spontaneously self-assembled into a micellar nano-preparation, which can be co-loaded with siRNA onto PAMAM moieties and sparingly water-soluble chemotherapeutics into the lipid hydrophobic core. This system was co-loaded with doxorubicin (DOX) and therapeutic siRNA (siMDR-1) and tested for cytotoxicity against MDR cancer cells: human ovarian carcinoma (A2780 ADR) and breast cancer (MCF7 ADR). The combination nanopreparation effectively downregulated P-gp in MDR cancer cells and reversed the resistance towards DOX.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: Chemotherapy; Combination delivery; Micelle; Mixed dendrimer micelles (MDM); Multidrug resistance; Polyamidoamine (PAMAM); siRNA delivery

Mesh：

Substances：

Year: 2019 PMID： 30633973 PMCID： PMC6377860 DOI： 10.1016/j.ejpb.2019.01.006

Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN： 0939-6411 Impact factor: 5.571

55 in total

1. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

Authors: M M Baekelandt; R Holm; J M Nesland; C G Tropé; G B Kristensen
Journal: Anticancer Res Date: 2000 Mar-Apr Impact factor: 2.480

2. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Authors: M Maliepaard; M A van Gastelen; L A de Jong; D Pluim; R C van Waardenburg; M C Ruevekamp-Helmers; B G Floot; J H Schellens
Journal: Cancer Res Date: 1999-09-15 Impact factor: 12.701

3. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

Authors: D Goren; A T Horowitz; D Tzemach; M Tarshish; S Zalipsky; A Gabizon
Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531

4. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

Authors: V P Torchilin; T S Levchenko; A N Lukyanov; B A Khaw; A L Klibanov; R Rammohan; G P Samokhin; K R Whiteman
Journal: Biochim Biophys Acta Date: 2001-04-02

5. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Authors: Muthu Selvakumaran; Debra A Pisarcik; Rudi Bao; Anthony T Yeung; Thomas C Hamilton
Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701

6. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

Authors: T Trippett; S Schlemmer; Y Elisseyeff; E Goker; M Wachter; P Steinherz; C Tan; E Berman; J E Wright; A Rosowsky
Journal: Blood Date: 1992-09-01 Impact factor: 22.113

Review 7. The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors: Danyelle M Townsend; Kenneth D Tew
Journal: Oncogene Date: 2003-10-20 Impact factor: 9.867

Review 8. Survivin, versatile modulation of cell division and apoptosis in cancer.

Authors: Dario C Altieri
Journal: Oncogene Date: 2003-11-24 Impact factor: 9.867

9. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

Authors: Henrik Gréen; Peter Söderkvist; Per Rosenberg; György Horvath; Curt Peterson
Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531

10. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

Authors: Raquel T Lima; Luís M Martins; José E Guimarães; Clara Sambade; M Helena Vasconcelos
Journal: Cancer Gene Ther Date: 2004-05 Impact factor: 5.987

15 in total

Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

1. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

2. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

3. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

4. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

5. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

6. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

Review 7. The role of glutathione-S-transferase in anti-cancer drug resistance.

Review 8. Survivin, versatile modulation of cell division and apoptosis in cancer.

9. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

10. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

1. Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay.

Review 2. Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity.

Review 3. Recent advances in anti-multidrug resistance for nano-drug delivery system.

Review 4. Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.

Review 5. Evolution of drug-eluting biomedical implants for sustained drug delivery.

6. Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery.

7. Oleyl Conjugated Histidine-Arginine Cell-Penetrating Peptides as Promising Agents for siRNA Delivery.

8. Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles.

Review 9. Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy.

Review 10. Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.